Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study

Authors: Wenjing Zhou, Karin Jirström, Christine Johansson, Rose-Marie Amini, Carl Blomqvist, Olorunsola Agbaje, Fredrik Wärnberg

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to study the prognosis of basal-like DCIS in a large population-based cohort.

Methods

All 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and Västmanland, Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical (IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models.

Results

IHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive. Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative or high grade DCIS.

Conclusions

Basal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better prognostic parameter than histopathological grade.
Appendix
Available only for authorised users
Literature
1.
Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, et al: Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC cancer. 2007, 7: 55-10.1186/1471-2407-7-55.CrossRefPubMedPubMedCentral
2.
Tsikitis VL, Chung MA: Biology of ductal carcinoma in situ classification based on biologic potential. American journal of clinical oncology. 2006, 29 (3): 305-310. 10.1097/01.coc.0000198740.33617.2f.CrossRefPubMed
3.
Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, Young LJ, Borowsky AD, Cardiff RD, Gregg JP: Heterogeneity of mammary lesions represent molecular differences. BMC cancer. 2006, 6: 275-10.1186/1471-2407-6-275.CrossRefPubMedPubMedCentral
4.
Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L: Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol. 2009, 100 (2): 89-94. 10.1002/jso.21307.CrossRefPubMed
5.
Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A: Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009, 20 (4): 628-635. 10.1093/annonc/mdn675.CrossRefPubMed
6.
Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009
7.
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009, 113 (2): 357-370. 10.1007/s10549-008-9926-3.CrossRefPubMed
8.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10 (4): R65.-10.1186/bcr2124.CrossRefPubMedPubMedCentral
9.
Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995, 270 (5235): 467-470. 10.1126/science.270.5235.467.CrossRefPubMed
10.
Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP: Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proceedings of the National Academy of Sciences of the United States of America. 1994, 91 (11): 5022-5026. 10.1073/pnas.91.11.5022.CrossRefPubMedPubMedCentral
11.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed
12.
Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006, 7: 127-10.1186/1471-2164-7-127.CrossRefPubMedPubMedCentral
13.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
14.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (14): 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
15.
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (18): 10393-10398. 10.1073/pnas.1732912100.CrossRefPubMedPubMedCentral
16.
Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005, 69 (6): 478-485. 10.1159/000090986.CrossRefPubMed
17.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
18.
Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007, 38 (2): 197-204. 10.1016/j.humpath.2006.08.017.CrossRefPubMed
19.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10 (16): 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRefPubMed
20.
Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006, 59 (7): 729-735. 10.1136/jcp.2005.033043.CrossRefPubMedPubMedCentral
21.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008, 14 (5): 1368-1376. 10.1158/1078-0432.CCR-07-1658.CrossRefPubMed
22.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006, 19 (2): 264-271. 10.1038/modpathol.3800528.CrossRefPubMed
23.
Warnberg F, Amini RM, Goldman M, Jirstrom K: Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast. Histopathology. 2008, 53 (6): 642-649. 10.1111/j.1365-2559.2008.03156.x.CrossRefPubMed
24.
Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G: Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer. 2003, 89 (10): 1920-1926. 10.1038/sj.bjc.6601398.CrossRefPubMedPubMedCentral
25.
Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, et al: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007, 9 (1): R16.-10.1186/bcr1649.CrossRefPubMedPubMedCentral
26.
Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 2007, 14 (10): 2994-3003. 10.1245/s10434-007-9477-6.CrossRefPubMed
27.
Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A: SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006, 45 (5): 536-543. 10.1080/02841860600681569.CrossRefPubMed
28.
Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005, 116 (3): 340-350. 10.1002/ijc.21004.CrossRefPubMed
29.
Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol. 2008, 39 (4): 506-513. 10.1016/j.humpath.2007.09.005.CrossRefPubMed
30.
Tang P, Skinner KA, Hicks DG: Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. Diagn Mol Pathol. 2009, 18 (3): 125-132. 10.1097/PDM.0b013e31818d107b.CrossRefPubMed
31.
Francis GD, Jones MA, Beadle GF, Stein SR: Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 2009, 18 (2): 88-95. 10.1097/PDM.0b013e31816f6374.CrossRefPubMed
32.
Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B: Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology. 2009, 54 (2): 248-253. 10.1111/j.1365-2559.2008.03185.x.CrossRefPubMed
33.
Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA: Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg. 2008, 247 (3): 463-469. 10.1097/SLA.0b013e31815d744a.CrossRefPubMed
34.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007, 16 (3): 439-443. 10.1158/1055-9965.EPI-06-0806.CrossRefPubMed
35.
36.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res. 2009, 7 (1-2): 4-13. 10.3121/cmr.2009.825.CrossRefPubMedPubMedCentral
37.
Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, Bois AD: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 2009
38.
Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009
39.
Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS, Tan PH: Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers. Am J Surg Pathol.
40.
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009, 15 (7): 2302-2310. 10.1158/1078-0432.CCR-08-2132.CrossRefPubMed
Metadata
Title
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study
Authors
Wenjing Zhou
Karin Jirström
Christine Johansson
Rose-Marie Amini
Carl Blomqvist
Olorunsola Agbaje
Fredrik Wärnberg
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-653

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Defensin alpha 6 (DEFA 6) overexpression threshold of over 60 fold can distinguish between adenoma and fully blown colon carcinoma in individual patients

Case report

Ectopic primary type A thymoma located in two thoracic vertebras: a case report

Research article

Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor

Research article

Irradiation-induced telomerase activity and gastric cancer risk: a case-control analysis in a Chinese Han population

Research article

Differential CARM1 expression in prostate and colorectal cancers

Research article

Prioritizing genes associated with prostate cancer development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits